<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recurrence of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) in the central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults </plain></SENT>
<SENT sid="1" pm="."><plain>For the current study, the authors analyzed the frequency, predictive factors, and prognosis of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis </plain></SENT>
<SENT sid="2" pm="."><plain>Four hundred sixty-seven adult patients (age &gt; or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt <z:hpo ids='HP_0001909'>leukemia</z:hpo>; n = 53 patients) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis consisted of intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> together with high-dose systemic <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The mean age (+/- standard deviation) was 33 years (+/- 16 years), and 272 patients were males </plain></SENT>
<SENT sid="5" pm="."><plain>ALL subtypes included an early pre-B phenotype (15%), a common phenotype (45%), a pre-B phenotype (5%), a mature B phenotype (11%), and a T phenotype (24%) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement at diagnosis was observed in 18 patients (3.9%) </plain></SENT>
<SENT sid="7" pm="."><plain>Of 159 recurrences, 22 occurred (5.8%) in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> (14 isolated and 8 combined) </plain></SENT>
<SENT sid="8" pm="."><plain>A <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase level &gt; 1000 U/L was the only factor associated with the risk of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> recurrence </plain></SENT>
<SENT sid="9" pm="."><plain>A complete remission was attained in 7 of 22 patients (32%) </plain></SENT>
<SENT sid="10" pm="."><plain>The median overall survival after recurrence was 0.7 years for patients with isolated <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> recurrence, 0.13 years for patients with combined recurrence, and 0.41 years for patients with bone marrow recurrence (P = .11) </plain></SENT>
<SENT sid="11" pm="."><plain>The only 2 survivors underwent stem cell transplantation </plain></SENT>
<SENT sid="12" pm="."><plain>The frequency of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> recurrence in adult patients with ALL who do not receive radiotherapy for <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis was similar to the frequency observed in protocols that included cranial irradiation </plain></SENT>
<SENT sid="13" pm="."><plain>A <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase value &gt;1000 U/L was the only factor found to be associated with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> recurrence </plain></SENT>
<SENT sid="14" pm="."><plain>The prognosis for patients who develop <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> recurrence is poor, identical to that for patients who develop bone marrow recurrence </plain></SENT>
</text></document>